JY231 injection for relapsed B-cell lymphoma or leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new injection called JY231 for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. The therapy targets a protein called CD19 on cancer cells, helping your immune system attack them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your cancer (B-cell lymphoma or leukemia) has come back or hasn't responded to standard treatments.
- Your cancer cells have a specific marker called CD19 on their surface (your doctor can check this).
- You haven't had a stem cell transplant in the last 6 months.
- You are in reasonably good health (good organ function and able to care for yourself).
- You have not received CAR-T therapy before, OR if you did, it's no longer active in your body.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (JY231) for people whose B-cell lymphoma or leukemia (B-ALL) has returned or not responded to earlier treatments. The therapy uses your own T cells, modified to target the CD19 marker on cancer cells.
This trial tests a new treatment, JY231, for people whose B-cell lymphoma has returned or stopped responding to previous therapies. It aims to see if JY231 can help shrink tumors or control the disease.
This trial tests a new cell therapy called JY231 for people whose B-cell lymphoma or leukemia has come back or not responded to standard treatments. The therapy targets a protein on cancer cells called CD19 and may help your immune system fight the cancer.
This trial tests a new treatment called JY231 for people with a type of blood cancer (B-cell leukemia) that has come back or not responded to standard treatments. It aims to see if this therapy can help control the cancer.
This trial tests a new cell therapy (JY231) for people with B-cell lymphoma or B-cell acute lymphoblastic leukemia (B-ALL) that has come back or didn't respond to previous treatments. The therapy targets a marker on cancer cells called CD19 and aims to help your body fight the cancer.
This trial tests a new treatment, JY231, for people with B-cell blood cancers that have come back or not responded to other treatments. It aims to see if this therapy can help when other options have stopped working.
Hear when a new B-Non Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.